Controlled release of transforming growth factor-β3 from cartilage-extra-cellular-matrix-derived scaffolds to promote chondrogenesis of human-joint-tissue-derived stem cells

Acta Biomater. 2014 Oct;10(10):4400-9. doi: 10.1016/j.actbio.2014.05.030. Epub 2014 Jun 4.

Abstract

The objective of this study was to develop a scaffold derived from cartilaginous extracellular matrix (ECM) that could be used as a growth factor delivery system to promote chondrogenesis of stem cells. Dehydrothermal crosslinked scaffolds were fabricated using a slurry of homogenized porcine articular cartilage, which was then seeded with human infrapatellar-fat-pad-derived stem cells (FPSCs). It was found that these ECM-derived scaffolds promoted superior chondrogenesis of FPSCs when the constructs were additionally stimulated with transforming growth factor (TGF)-β3. Cell-mediated contraction of the scaffold was observed, which could be limited by the additional use of 1-ethyl-3-3dimethyl aminopropyl carbodiimide (EDAC) crosslinking without suppressing cartilage-specific matrix accumulation within the construct. To further validate the utility of the ECM-derived scaffold, we next compared its chondro-permissive properties to a biomimetic collagen-hyaluronic acid (HA) scaffold optimized for cartilage tissue engineering (TE) applications. The cartilage-ECM-derived scaffold supported at least comparable chondrogenesis to the collagen-HA scaffold, underwent less contraction and retained a greater proportion of synthesized sulfated glycosaminoglycans. Having developed a promising scaffold for TE, with superior chondrogenesis observed in the presence of exogenously supplied TGF-β3, the final phase of the study explored whether this scaffold could be used as a TGF-β3 delivery system to promote chondrogenesis of FPSCs. It was found that the majority of TGF-β3 that was loaded onto the scaffold was released in a controlled manner over the first 10days of culture, with comparable long-term chondrogenesis observed in these TGF-β3-loaded constructs compared to scaffolds where the TGF-β3 was continuously added to the media. The results of this study support the use of cartilage-ECM-derived scaffolds as a growth factor delivery system for use in articular cartilage regeneration.

Keywords: Articular cartilage; Crosslinking; Extracellular matrix; Stem cells; Tissue engineering.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomimetic Materials / chemistry
  • Biomimetic Materials / pharmacology
  • Cartilage, Articular / cytology
  • Cartilage, Articular / metabolism
  • Chondrogenesis / drug effects*
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacology
  • Extracellular Matrix / chemistry*
  • Female
  • Humans
  • Hyaluronic Acid / chemistry
  • Hyaluronic Acid / pharmacology
  • Joints / cytology
  • Joints / metabolism*
  • Male
  • Regeneration / drug effects
  • Stem Cells / cytology
  • Stem Cells / metabolism*
  • Tissue Scaffolds / chemistry*
  • Transforming Growth Factor beta3* / chemistry
  • Transforming Growth Factor beta3* / pharmacology

Substances

  • Delayed-Action Preparations
  • TGFB3 protein, human
  • Transforming Growth Factor beta3
  • Hyaluronic Acid